U.S., Aug. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07113418) titled 'Role of FGF21 in Breast Cancer' on July 22.
Brief Summary: The present study aims to evaluate the serum level of FGF-21 in patients with breast cancer and its correlation with clinical, laboratory, and pathological data.
Study Start Date: Sept., 2025
Study Type: OBSERVATIONAL
Condition:
Breast Cancer
Intervention:
DIAGNOSTIC_TEST: ELISA
Enzyme-Linked Immunosorbent Assay. It's a lab technique used to detect and measure specific proteins like antibodies or antigens in a biological sample using enzyme-linked antibodies. When a substrate is added, the enzyme causes a color change, which makes it easy to measure the result accurate...